‘Frustration’ of doctors seeing the beneficial restriction over Umckamin Syrup
.jpg)
While pharmaceutical companies are opposing to the beneficial restriction of an antitussive expectorant, Umckamin Syrup, clinical institutions has also criticized about the issue.
The cause of the beneficial restriction of Umckamin Syrup is the insurance approval standard of liquid drugs (such a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
